English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17419/19718 (88%)
Visitors : 6182494      Online Users : 729
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/30981

    標題: Cost-effectiveness of Gemcitabine Plus Modern Radiotherapy in Locally Advanced Pancreatic Cancer
    作者: Leung, Henry W. C.
    Chan, Agnes L. F.
    Muo, Chih-Hsin
    貢獻者: China Med Univ, An Nan Hosp, Dept Radiat Therapy
    Chia Nan Univ Pharm & Sci, Dept Informat Management
    China Med Univ, An Nan Hosp, Dept Pharm
    Chia Nan Univ Pharm & Sci, Dept Pharm
    China Med Univ Hosp, Management Off Hlth Data
    關鍵字: cost-effectiveness
    economic evaluation
    locally advanced pancreatic cancer
    stereotactic body radiotherapy
    日期: 2016-05
    上傳時間: 2018-01-18 11:39:09 (UTC+8)
    出版者: Elsevier
    摘要: Purpose: The purpose of this study was to evaluate the cost-effectiveness of gemcitabine plus modern radiotherapy versus gemcitabine alone in the treatment of locally advanced pancreatic cancer in Taiwan. Methods: A Markov decision-analytic model was performed to compare the cost-effectiveness of 3 treatment regimens; gemcitabine alone (gem-alone), gemcitabine plus intensity-modulated radiotherapy (gem-IMRT), and gemcitabine plus stereotactic body radiotherapy (gem-SBRT). Patients transitioned between 5 health states: stable disease, local progression, distant metastasis, local and distant metastasis, and death. Findings: The incremental cost-effectiveness ratio for gem-IMRT and gem-SBRT compared with gem alone were NT$27,120,168 and NT$2,145,683 per quality-adjusted life-year gained, respectively. A willingness to pay threshold of 3 times the per capita gross domestic product was adopted according to the definition of the World Health Organization. The Taiwan per capita gross domestic product in 2015 was NT$673,920 (US$22,464; 1 NT$ = US$0.03333 in Taiwan); thus, a threshold was considered as NT $2,021,760 (US$67,392). The Monte-Carlo simulation found that the probability of cost-effectiveness at a willingness to pay threshold of NT$2,021,760 per quality-adjusted life-year was 0% chance for gem-IMRT and 50% for gem-SBRT. Implications: This study indicated that gem-IMRT or gem-SBRT in locally advanced pancreatic cancer is not cost-effective at a willingness to pay as defined by World Health Organization guideline in Taiwan. (C) 2016 Elsevier HS Journals, Inc. All rights reserved.
    關聯: Clinical Therapeutics, v.38 n.5, pp.1174-1183
    Appears in Collections:[藥學系(所)] 期刊論文
    [資訊管理系] 期刊論文

    Files in This Item:

    File Description SizeFormat

    All items in CNU IR are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback